Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
November 08 2016 - 8:00AM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative medicines and other products for targeting
and treating cancer, today announced that Mark Baker, Chief
Executive Officer, will present at two upcoming investor
conferences:
- Presentation at the Stifel 2016 Healthcare Conference on
Tuesday, November 15, 2016 at 3:45 p.m. Eastern Time. The
conference is being held at the Lotte New York Palace Hotel in New
York City.
- Presentation at the Jefferies London Healthcare Conference on
Thursday, November 17, 2016 at 9:20 a.m. Greenwich Mean Time.
The conference is being held at the Waldorf Hilton in London,
UK.
A live webcast of both the Stifel and Jefferies
presentations will be available in the Media Center of the
Progenics website, www.progenics.com. To ensure a timely
connection, users should register at least 15 minutes prior to the
scheduled start. An archive of the events will be available for 90
days.
About Progenics
Progenics Pharmaceuticals, Inc. is developing
innovative medicines and other products for targeting and treating
cancer, with a pipeline that includes several product candidates in
later-stage clinical development. These products in
development include therapeutic agents designed to precisely target
cancer (AZEDRA® and 1095), and PSMA-targeted imaging agents for
prostate cancer (1404 and PyLTM) intended to enable clinicians and
patients to accurately visualize and manage their disease. In
addition, in late 2015 Progenics acquired EXINI Diagnostics AB, a
leader in the development of advanced artificial intelligence-based
imaging analysis tools and solutions for medical decision support.
The acquisition of EXINI complements Progenics’ strategy to
support its imaging and therapeutic agents with sophisticated
analytical tools and other technologies to help physicians and
patients visualize, understand, target and treat cancer.
Progenics’ first commercial product, RELISTOR® (methylnaltrexone
bromide) for opioid-induced constipation, is partnered with and
marketed by Valeant Pharmaceuticals International, Inc.
This press release may contain projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations, such as our
collaboration with Valeant on the RELISTOR oral formulation and the
Phase 3 clinical program for 1404; our ability to successfully
integrate EXINI Diagnostics AB and to develop and commercialize its
products; the unpredictability of the duration and results of
regulatory review of New Drug Applications and Investigational
NDAs; market acceptance for approved products; the effectiveness of
the efforts of our partners to market and sell products on which we
collaborate and the royalty revenue generated thereby; generic and
other competition; the possible impairment of, inability to obtain
and costs of obtaining intellectual property rights; possible
product safety or efficacy concerns, general business, financial
and accounting matters, litigation and other risks. More
information concerning Progenics and such risks and uncertainties
is available on its website, and in its press releases and reports
it files with the U.S. Securities and Exchange Commission.
Progenics is providing the information in this press release as of
its date and, except as expressly required by law, Progenics
disclaims any intent or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or circumstances or otherwise.
Additional information concerning Progenics and its
business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Please follow us on
LinkedIn®. Information on or accessed through our website or social
media sites is not included in the company's SEC filings.
(PGNX-F)
Contact:
Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024